Piramal, CEO Vivek Sharma Receives ‘CEO of the Year’ Award
News Oct 23, 2015
Piramal Enterprises' Pharma Solutions division each year participates at CPhI Worldwide. This is a convention that brings together the global pharmaceutical community to meet and identify business opportunities.
At the annual CPhI Pharma Awards this year, Piramal Pharma Solutions (PPS) took center-stage, with Vivek Sharma, CEO-Pharma Solutions, Piramal Enterprises receiving CPhI’s ‘CEO of the Year Award’ for 2015. This award was given by Pharmaceutical Executive Editor-in-Chief, William Looney, at a ceremony in Madrid, Spain, on Wednesday, Oct 14, 2015.
The CPhI Pharma Awards recognize life sciences firms that turn inspiration into innovation, and celebrate thinkers and creators that are breaking new ground in formulation, process development, packaging, technology, and more.
Vivek Sharma, CEO-Pharma Solutions, Piramal Enterprises said, “I receive this award on behalf of my team and everyone at Piramal. It has been a pleasure working with my highly motivated colleagues that come to work every day with the goal of delivering medicines on time and of the highest quality. I am greatly humbled, and thank our customers for having given us an opportunity to serve them. This week has been a memorable one for us as we also won the API Supplier of the year, 2015”.
Under Vivek Sharma’s leadership, PPS has established itself as the partner of choice for both large pharma and biotech firms, by focusing on the pillars of customer centricity, quality, and innovation. These initiatives have led Piramal to be voted amongst the global top 10% contract manufacturing organizations (CMO) for both 2014 and 2015, in key categories such has quality and reliability.
Piramal’s leadership in antibody drug conjugates (ADCs) has been widely recognized, with Piramal Pharma Solutions receiving the ‘Best Contract Provider for ADC’, at the World ADC Awards, 2014. Timely investments in rapidly growing segments such as ADCs, steriles, manufacturing and hormonals have also fuelled its success story.
Vivek added, “Although I do not have a healthcare background, I enjoy getting involved into the details. I bring my experience of over 20 years in operations and finance to drive efficiency, yet I learn from everyone around me. My role is to make my team successful, and we have worked hard at bringing in talent who are global experts in their respective areas. It has been a great start – we hope to build on this, and continue to deliver value to our stakeholders and our clients.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018